EMA Recommends Marketing Authorization For Donanemab (Kisunla)
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab (Kisunla) for the treatment of…
Read more...